Advanced search
Publication Cover
Modern Rheumatology Volume 22, 2012 - Issue 4
Journal homepage
40
Views
18
CrossRef citations to date
0
Altmetric
Case Report

Morphea associated with the use of adalimumab: a case report and review of the literature

Julio RamírezArthritis Unit, Department of Rheumatology, Hospital Clinic, University of Barcelona, Villarroel 170, Stairway 11, 2nd Floor, 08036 Barcelona, SpainCorrespondence[email protected]
,
M. Victoria HernándezArthritis Unit, Department of Rheumatology, Hospital Clinic, University of Barcelona, Villarroel 170, Stairway 11, 2nd Floor, 08036 Barcelona, Spain
,
Javier GalveDepartment of Dermatology, Hospital Clinic, University of Barcelona, Barcelona, Spain
,
Juan D. CañeteArthritis Unit, Department of Rheumatology, Hospital Clinic, University of Barcelona, Villarroel 170, Stairway 11, 2nd Floor, 08036 Barcelona, Spain
&
Raimon SanmartíArthritis Unit, Department of Rheumatology, Hospital Clinic, University of Barcelona, Villarroel 170, Stairway 11, 2nd Floor, 08036 Barcelona, Spain
Pages 602-604 | Received 26 Jul 2011, Accepted 28 Sep 2011, Published online: 02 Jan 2014

References

  • Bonds-Blasco J, Navarro-Ruiz A, Bonds C, Casterd E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009;102:1133–40.
  • Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-a-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666–76.
  • Lee HH, Song IH, Friedich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-a antagonists. Br J Dermatol. 2007;156:486–91.
  • Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50: 1400–11.
  • Dalmau J, Roe E, Corella F, Garcia-Navarro X, Peramiquel L, Alomar A. Acute generalized skin eruption due to adalimumab: report of two cases. J Eur Acad Dermatol V enereol. 2007;21:1105–6.
  • Garcia Bartels N, Lee HH, Worm M, Burmester GR, Sterry W, Blume-Peytavi U. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol. 2006;142:1654–5.
  • Rajpara SN, Ormerod AD, Gallaway L. Adalimumab-induced pityriasis rosea. J Eur Acad Dermatol Venereol. 2007;21:1294–6.
  • Nikas SN, Voulgari PV, Drosos AA. Urticaria and angioedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol. 2007;26:787–8.
  • Beuthien W, Mellinghoff HH, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004;50:1690–2.
  • Salama M, Lawrance IC. Stevens-Johnson syndrome compli-cating adalimumab therapy in Crohn's disease. World J Gastro-enterol. 2009;15:4449–52.
  • FDA US Food and drug administration. Tumor necrosis factor alpha (TNF-a) antagonists [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: serious skin reactions. Postmarketing Rev. 2008;1(2). http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ ucm119034.htm#tnf.
  • Ranganathan P. Infliximab-induced scleroderma in a patient with rheumatoid arthritis. J Clin Rheumatol. 2005;11:319–22.
  • Mattozzi C, Richetta AG, Cantisani C, et al. Morphea, an unusual side effect of anti-TNF-alpha treatment. Eur J Dermatol. 2010;20: 400–1.
  • Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol. 2008;20:601–7.
  • Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology. 2009;48: 213–21.
  • Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demon-stration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995;287(2):193–7.
  • Kurzinski K, Torok KS. Cytokines profiles in localized scleroderma and relationship to clinical features. Citokine. 2011;55:157–64.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.